Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

162 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel bone-targeting agents in prostate cancer.
Albany C, Hahn NM. Albany C, et al. Among authors: hahn nm. Prostate Cancer Prostatic Dis. 2014 Jun;17(2):112-8. doi: 10.1038/pcan.2014.12. Epub 2014 Mar 25. Prostate Cancer Prostatic Dis. 2014. PMID: 24662963 Review.
Epigenetics in prostate cancer.
Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM. Albany C, et al. Among authors: hahn nm. Prostate Cancer. 2011;2011:580318. doi: 10.1155/2011/580318. Epub 2011 Nov 30. Prostate Cancer. 2011. PMID: 22191037 Free PMC article.
Phase 2 trial of the topoisomerase II inhibitor, amrubicin, as second-line therapy in patients with metastatic urothelial carcinoma.
Galsky MD, Hahn NM, Wong B, Lee KM, Argiriadi P, Albany C, Gimpel-Tetra K, Lowe N, Shahin M, Patel V, Tsao CK, Oh WK. Galsky MD, et al. Among authors: hahn nm. Cancer Chemother Pharmacol. 2015 Dec;76(6):1259-65. doi: 10.1007/s00280-015-2884-7. Epub 2015 Oct 13. Cancer Chemother Pharmacol. 2015. PMID: 26464352 Clinical Trial.
A Phase II Trial of Dovitinib in BCG-Unresponsive Urothelial Carcinoma with FGFR3 Mutations or Overexpression: Hoosier Cancer Research Network Trial HCRN 12-157.
Hahn NM, Bivalacqua TJ, Ross AE, Netto GJ, Baras A, Park JC, Chapman C, Masterson TA, Koch MO, Bihrle R, Foster RS, Gardner TA, Cheng L, Jones DR, McElyea K, Sandusky GE, Breen T, Liu Z, Albany C, Moore ML, Loman RL, Reed A, Turner SA, De Abreu FB, Gallagher T, Tsongalis GJ, Plimack ER, Greenberg RE, Geynisman DM. Hahn NM, et al. Clin Cancer Res. 2017 Jun 15;23(12):3003-3011. doi: 10.1158/1078-0432.CCR-16-2267. Epub 2016 Dec 8. Clin Cancer Res. 2017. PMID: 27932416 Free PMC article. Clinical Trial.
Prognostic Effect of Carcinoma In Situ in Muscle-invasive Urothelial Carcinoma Patients Receiving Neoadjuvant Chemotherapy.
Thomas DE, Kaimakliotis HZ, Rice KR, Pereira JA, Johnston P, Moore ML, Reed A, Cregar DM, Franklin C, Loman RL, Koch MO, Bihrle R, Foster RS, Masterson TA, Gardner TA, Sundaram CP, Powell CR, Beck SDW, Grignon DJ, Cheng L, Albany C, Hahn NM. Thomas DE, et al. Among authors: hahn nm. Clin Genitourin Cancer. 2017 Aug;15(4):479-486. doi: 10.1016/j.clgc.2016.11.009. Epub 2016 Nov 30. Clin Genitourin Cancer. 2017. PMID: 28040424 Free PMC article.
Phase 2 Trial of Gemcitabine, Cisplatin, plus Ipilimumab in Patients with Metastatic Urothelial Cancer and Impact of DNA Damage Response Gene Mutations on Outcomes.
Galsky MD, Wang H, Hahn NM, Twardowski P, Pal SK, Albany C, Fleming MT, Starodub A, Hauke RJ, Yu M, Zhao Q, Sonpavde G, Donovan MJ, Patel VG, Sfakianos JP, Domingo-Domenech J, Oh WK, Akers N, Losic B, Gnjatic S, Schadt EE, Chen R, Kim-Schulze S, Bhardwaj N, Uzilov AV. Galsky MD, et al. Among authors: hahn nm. Eur Urol. 2018 May;73(5):751-759. doi: 10.1016/j.eururo.2017.12.001. Epub 2017 Dec 13. Eur Urol. 2018. PMID: 29248319 Clinical Trial.
162 results